These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
10. Lentiviral-mediated gene transfer of siRNAs for the treatment of Huntington's disease. Cambon K; Déglon N Methods Mol Biol; 2013; 1010():95-109. PubMed ID: 23754221 [TBL] [Abstract][Full Text] [Related]
11. Huntington disease and the huntingtin protein. Zheng Z; Diamond MI Prog Mol Biol Transl Sci; 2012; 107():189-214. PubMed ID: 22482451 [TBL] [Abstract][Full Text] [Related]
12. Presence of tau pathology within foetal neural allografts in patients with Huntington's and Parkinson's disease. Cisbani G; Maxan A; Kordower JH; Planel E; Freeman TB; Cicchetti F Brain; 2017 Nov; 140(11):2982-2992. PubMed ID: 29069396 [TBL] [Abstract][Full Text] [Related]
15. Development of novel therapies for Huntington's disease: hope and challenge. Qin ZH; Wang J; Gu ZL Acta Pharmacol Sin; 2005 Feb; 26(2):129-42. PubMed ID: 15663888 [TBL] [Abstract][Full Text] [Related]
16. Therapeutic strategies for Huntington's disease based on a molecular understanding of the disorder. Haque NS; Borghesani P; Isacson O Mol Med Today; 1997 Apr; 3(4):175-83. PubMed ID: 9134531 [TBL] [Abstract][Full Text] [Related]
19. [Mechanisms of neuronal death in Huntington's disease. First part: general considerations and histopathological features]. Bantubungi K; Blum D Rev Med Brux; 2007; 28(5):413-21. PubMed ID: 18069515 [TBL] [Abstract][Full Text] [Related]
20. Preventing formation of toxic N-terminal huntingtin fragments through antisense oligonucleotide-mediated protein modification. Evers MM; Tran HD; Zalachoras I; Meijer OC; den Dunnen JT; van Ommen GJ; Aartsma-Rus A; van Roon-Mom WM Nucleic Acid Ther; 2014 Feb; 24(1):4-12. PubMed ID: 24380395 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]